SK Bioscience wins patent lawsuit against Pfizer (PFE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Pfizer (PFE) PT Raised to $33 at Jefferies
May 21, 2025 8:19 AM EDTJefferies analyst Akash Tewari raised the price target on Pfizer (NYSE: PFE) to $33.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "PFE announced an exclusive global licensing agreement w/ 3SBio for SSGJ-707 (PD-1/VEGF). We like the deal for PFE:... More
